1
|
Arni D, Gumy-Pause F, Ansari M, Belli D, Kremer Hovinga J, McLin V. Transplantation hépatique réussie après une insuffisance hépatique aiguë et un purpura thrombocytopénique thrombotique acquis. Arch Pediatr 2016. [DOI: 10.1016/j.arcped.2016.02.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
2
|
Carnesecchi S, Rougemont AL, Doroshow JH, Nagy M, Mouche S, Gumy-Pause F, Szanto I. The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines. Free Radic Biol Med 2015; 84:22-29. [PMID: 25797883 PMCID: PMC7735533 DOI: 10.1016/j.freeradbiomed.2015.02.027] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Revised: 02/22/2015] [Accepted: 02/24/2015] [Indexed: 01/11/2023]
Abstract
Reactive oxygen species (ROS) are key modulators of apoptosis and carcinogenesis. One of the important sources of ROS is NADPH oxidases (NOXs). The isoform NOX5 is highly expressed in lymphoid tissues, but it has not been detected in any common Hodgkin or non-Hodgkin lymphoma cell lines. In diverse, nonlymphoid malignant cells NOX5 exerts an antiapoptotic effect. Apoptosis suppression is the hallmark feature of a rare type of lymphoma, termed anaplastic lymphoma kinase-positive (ALK(+)) anaplastic large-cell lymphoma (ALCL), and a major factor in the therapy resistance and relapse of ALK(+) ALCL tumors. We applied RT-PCR and Western blot analysis to detect NOX5 expression in three ALK(+) ALCL cell lines (Karpas-299, SR-786, SUP-M2). We investigated the role of NOX5 in apoptosis by small-interfering RNA (siRNA)-mediated gene silencing and chemical inhibition of NOX5 using FACS analysis and examining caspase 3 cleavage in Karpas-299 cells. We used immunohistochemistry to detect NOX5 in ALK(+) ALCL pediatric tumors. NOX5 mRNA was uniquely detected in ALK(+) ALCL cells, whereas cell lines of other lymphoma classes were devoid of NOX5. Transfection of NOX5-specific siRNA and chemical inhibition of NOX5 abrogated calcium-induced superoxide production and increased caspase 3-mediated apoptosis in Karpas-299 cells. Immunohistochemistry revealed focal NOX5 reactivity in pediatric ALK(+) ALCL tumor cells. These results indicate that NOX5-derived ROS contribute to apoptosis blockage in ALK(+) ALCL cell lines and suggest NOX5 as a potential pharmaceutical target to enhance apoptosis and thus to suppress tumor progression and prevent relapse in pediatric ALK(+) ALCL patients that resist classical therapeutic approaches.
Collapse
Affiliation(s)
- S Carnesecchi
- Department of Cellular Physiology and Metabolism and; Department of Pathology and Immunology, University of Geneva, CH-1211 Geneva 4, Switzerland
| | | | - J H Doroshow
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - M Nagy
- Department of Pathology and Immunology, University of Geneva, CH-1211 Geneva 4, Switzerland
| | - S Mouche
- Department of Cellular Physiology and Metabolism and
| | - F Gumy-Pause
- Department of Pediatrics, Hematology/Oncology Unit, CANSEARCH Research Laboratory, Geneva, Switzerland
| | - I Szanto
- Department of Cellular Physiology and Metabolism and; Department of Internal Medicine Specialties, University Hospitals of Geneva, Geneva, Switzerland.
| |
Collapse
|
3
|
Rock N, Mattiello V, Judas C, Huezo-Diaz P, Bourquin JP, Gumy-Pause F, Ansari M. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child. Pediatr Hematol Oncol 2014; 31:143-8. [PMID: 24498972 DOI: 10.3109/08880018.2013.876470] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
In adult therapy, arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) are recognized as active treatment of relapsed acute promyelocytic leukemia (APL). The efficacy of this combination in pediatric APL has not yet been well established. We report the case of a 6-year-old girl with relapsed APL, with a PML-RARα mutation, treated with a combination of ATO and ATRA. Over a period of 5 months, she received in total, 75 doses of intravenous ATO and 40 doses of oral ATRA. Currently, 22 months after relapse, she is still in complete remission. Here, we describe treatment of a relapsed APL in a child with limited treatment of ATO and ATRA and review the literature.
Collapse
Affiliation(s)
- Nathalie Rock
- Hemato-Oncology Unit, Department of Pediatrics, University Hospital of Geneva, Geneva, Switzerland
| | | | | | | | | | | | | |
Collapse
|
4
|
Uppugunduri C, Ansari M, Théorêt Y, Déglon J, Versace F, Gumy-Pause F, Dayer P, Desmeules J, Daali Y. Oc013 — A Simplified Method For Busulfan Therapeutic Drug Monitoring Using Dried Blood Spot Sampling In Pediatric Patient Undergoing Stem Cell Transplantation. Clin Ther 2013. [DOI: 10.1016/j.clinthera.2013.07.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
5
|
Sappino AP, Buser R, Seguin Q, Fernet M, Lesne L, Gumy-Pause F, Reith W, Favaudon V, Mandriota SJ. The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage. Oncogenesis 2012; 1:e7. [PMID: 23552604 PMCID: PMC3412640 DOI: 10.1038/oncsis.2012.7] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
The p53 tumor-suppressor protein has a key role in the induction of cellular senescence, an important barrier to cancer development. However, very little is known about the physiological mediators of cellular senescence induced by p53. CEACAM1 is an immunoglobulin superfamily member whose expression is frequently lost in human tumors and exhibits tumor-suppressor features in several experimental systems, including Ceacam1 knockout mice. There is currently little understanding of the pathways and mechanisms by which CEACAM1 exerts its tumor-suppressor function. Here we report that CEACAM1 is strongly upregulated during the cellular response to DNA double-strand breaks (DSBs) starting from the lowest doses of DSB inducers used, and that upregulation is mediated by the ataxia telangiectasia mutated (ATM)/p53 pathway. Stable silencing of CEACAM1 showed that CEACAM1 is required for p53-mediated cellular senescence, but not initial cell growth arrest, in response to DNA damage. These findings identify CEACAM1 as a key component of the ATM/p53-mediated cellular response to DNA damage, and as a tumor suppressor mediating cellular senescence downstream of p53.
Collapse
Affiliation(s)
- A-P Sappino
- Clinique des Grangettes, Geneva, Switzerland
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Ansari M, Vukicevic M, Rougemont AL, Moll S, Parvex P, Gumy-Pause F, Chalandon Y, Passweg J, Ozsahin H, Roosnek E. Do NK cells contribute to the pathophysiology of transplant-associated thrombotic microangiopathy? Am J Transplant 2011; 11:1748-52. [PMID: 21714846 DOI: 10.1111/j.1600-6143.2011.03617.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Transplant-associated thrombotic microangiopathy (TA-TMA) is a life-threatening complication caused by the aggregation of platelets exposed to the thrombogenic subendothelial matrix of injured endothelial cells. Here, we present a case of a patient transplanted for idiopathic aplastic anemia with a T-cell depleted hematopoietic stem cell graft from an HLA-C mismatched unrelated donor. At day 7 posttransplant, she suffered from acute renal failure with hematuria. The presence of numerous schistocytes, an increased level of lactate dehydrogenase and a renal biopsy with multiple vascular injuries confirmed the diagnosis of severe TA-TMA. At day 14, she developed graft versus host disease and died 7 months posttransplantation of multiorgan failure. At day 15, we observed a sizable population of natural killer (NK) cells in the peripheral blood, the number of which reached 0.8 G/L at 4 months posttransplant. Most NK cells lacked inhibitory killer immunoglobulin-like receptors (KIR) specific for the KIR-ligands expressed in the patient. NK cells were also abundantly present in pericardial and pleural fluids and had invaded the kidney, where they colocalized with the renal vasculopathy. Because there are several mechanisms through which NK cells and platelets can activate each other reciprocally, it is conceivable that NK cells contribute to TA-TMA and its progression.
Collapse
Affiliation(s)
- M Ansari
- Department of Pediatrics, University Hospital of Geneva, Switzerland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Gumy-Pause F, Pardo B, Khoshbeen-Boudal M, Ansari M, Attiyeh EF, Ozsahin H. Association of GSTP1 hypermethylation with reduced protein expression and its correlation with clinical stage in neuroblastoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.9537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Gumy-Pause F, Ozsahin H, Khoshbeen-Boudal M, Pardo B, Betts D, Maillet P, Sappino A. ATM gene analysis in neuroblastoma: A report from the COG. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10058 Background: Neuroblastoma (NB) is the most common malignant disease of infancy and accounts for approximately 8% of all childhood cancers. The clinical hallmark of this tumor is the marked variability in prognosis depending of the age, stage, and biological characteristics. There is evidence to suggest that the long arm of chromosome 11 (11q) plays a role in NB biology. The ATM gene is located at 11q22–23 and hereditary mutations of this gene cause ataxia-telangiectasia, a recessive disorder associated with a high incidence of neoplasia. The aim of this project was to determine the prevalence of ATM gene mutation and ATM methylation status in 50 NB samples. Methods: Following DNA extraction, PCR products of the 65 exons of the ATM gene and its promoter were screened by DHPLC. This screening was also performed on DNA from 60 blood donors. Alterations detected were analyzed by direct sequencing. Direct and indirect criteria were used to classify the observed nucleotide alterations as mutation (if pathogenic), rare variant (if the allelic frequency in controls was < or = 1%), variant (1.1–2.4%) or polymorphism (> or = 2.5%). The ATM methylation status was analyzed by MS-MLPA (Methylation-Specific Multiplex Ligation-dependent Probe Amplification). Results: Except polymorphisms, 17 different sequence alterations were found in 17 NB samples (34%). Ten of these 17 alterations, found in 11 NB (22%), were rare variants (RV). In 5 NB (10%), RV were found homozygous. At the same time, we found 20 different sequence alterations in 19 controls (32%). Sixteen of these 20 alterations were RV and one was a heterozygous pathogenic mutation. These 17 alterations concern 15 controls (25%). No homozygous RV was found in controls. We found no evidence of ATM promoter hypermethylation in the 48 NB samples analyzed. Conclusions: We found no difference in ATMvariant and RV frequency between NB and control samples. However, as ATM deletion is a frequent event in NB, we found a high frequency of homozygous RV (10%). At present, we are completing this study by screening ATMlarge genomic deletion/duplication using MLPA. Finally, our observations indicate that epigenetic ATM silencing by methylation is uncommon in neuroblastoma. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- F. Gumy-Pause
- University Hospital of Geneva, Geneva, Switzerland; University Children's Hospital, Zurich, Switzerland
| | - H. Ozsahin
- University Hospital of Geneva, Geneva, Switzerland; University Children's Hospital, Zurich, Switzerland
| | - M. Khoshbeen-Boudal
- University Hospital of Geneva, Geneva, Switzerland; University Children's Hospital, Zurich, Switzerland
| | - B. Pardo
- University Hospital of Geneva, Geneva, Switzerland; University Children's Hospital, Zurich, Switzerland
| | - D. Betts
- University Hospital of Geneva, Geneva, Switzerland; University Children's Hospital, Zurich, Switzerland
| | - P. Maillet
- University Hospital of Geneva, Geneva, Switzerland; University Children's Hospital, Zurich, Switzerland
| | - A. Sappino
- University Hospital of Geneva, Geneva, Switzerland; University Children's Hospital, Zurich, Switzerland
| |
Collapse
|
9
|
Gumy-Pause F, Wacker P, Maillet P, Betts DR, Sappino AP. ATM variants and predisposition to childhood T-lineage acute lymphoblastic leukaemia. Leukemia 2006; 20:526-7; author reply 527. [PMID: 16408093 DOI: 10.1038/sj.leu.2404091] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
10
|
Gumy-Pause F, Wacker P, Maillet P, Betts D, Sappino AP. ATM gene promoter analysis in childhood lymphoid malignancies. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8512] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Gumy-Pause
- Univ Hosp of Geneva, Geneva, Switzerland; Univ Children’s Hosp of Zurich, Zurich, Switzerland
| | - P. Wacker
- Univ Hosp of Geneva, Geneva, Switzerland; Univ Children’s Hosp of Zurich, Zurich, Switzerland
| | - P. Maillet
- Univ Hosp of Geneva, Geneva, Switzerland; Univ Children’s Hosp of Zurich, Zurich, Switzerland
| | - D. Betts
- Univ Hosp of Geneva, Geneva, Switzerland; Univ Children’s Hosp of Zurich, Zurich, Switzerland
| | - A.-P. Sappino
- Univ Hosp of Geneva, Geneva, Switzerland; Univ Children’s Hosp of Zurich, Zurich, Switzerland
| |
Collapse
|
11
|
Abstract
Inherited biallelic mutations of the ATM (ataxia-telangiectasia mutated) gene cause ataxia-telangiectasia, a rare autosomal recessive disorder associated with a high incidence of childhood leukaemias and lymphomas, suggesting that ATM gene alterations may be involved in lymphomagenesis. Loss of heterozygosity at 11q22-23 (location of the ATM gene) is a frequent event in sporadic lymphoid tumours, and several studies have reported a high prevalence of ATM gene alterations in diverse sporadic lymphoproliferative disorders, adding evidence to the postulated contribution of ATM in the pathogenesis of these tumours. This mini-review will summarize the recently published data concerning the ATM gene in sporadic lymphoid malignancies and will discuss the apparent paradox between the predominance of nonsense mutations observed in patient with ataxia-telangiectasia and the high proportion of missense alterations found in sporadic lymphoid tumours.
Collapse
Affiliation(s)
- F Gumy-Pause
- Department of Pediatrics, Hematology/Oncology Unit, University Hospital of Geneva, Switzerland.
| | | | | |
Collapse
|